Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Thalidomide BMS (previously Thalidomide Celgene)
Thalidomide BMS 50 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-118541 · Präparat HOS-094839
Medicinal products known to be associated with peripheral neuropathy (e.g. vincristine and
bortezomib) should be used with caution in patients receiving thalidomide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vincristine (HOS-086219) bortezomib (HOS-110227)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-22T16:42:00Z · SHA-256 537c04bf4162671fd0a63561bed97ea3a0b2ca75db8df09543c26a61de067575 · Passage d2100c51d99d1cf064bca19278eaad840f6b9a5dadee617d90cc8e040d5c33c3 · Zeichen 1050–1215 im Abschnitt
Wechselwirkungen · NexoBrid
NexoBrid 5 g powder and gel for gel · Abschnitt 4.5 · PDF-Seite 7
HOS-213882 · Präparat HOS-155226
Fluorouracil and vincristine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vincristine (HOS-086219) fluorouracil (HOS-086023)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T16:44:00Z · SHA-256 0e966e92cc19adf0ef382cd0ae4ca84db51705148a696b737819286b20db4bab · Passage 00c6ddef52916ff033932465a8b3addea7419ccb430bf0d049fc7554b8d747b7 · Zeichen 1221–1249 im Abschnitt
Wechselwirkungen · NexoBrid
NexoBrid 5 g powder and gel for gel · Abschnitt 4.5 · PDF-Seite 7
HOS-213885 · Präparat HOS-155226
Bromelain may enhance the actions of fluorouracil and vincristine. Patients should be monitored for
increased toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vincristine (HOS-086219) fluorouracil (HOS-086023)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T16:44:00Z · SHA-256 0e966e92cc19adf0ef382cd0ae4ca84db51705148a696b737819286b20db4bab · Passage 3a917e6f35edb27829a3df20919b068c85c1fa197258f1aad117f3e438e7857f · Zeichen 1251–1370 im Abschnitt
Wechselwirkungen · Spectrila
Spectrila 10,000 U powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-128258 · Präparat HOS-096541
Vincristine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vincristine (HOS-086219)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T12:00:00Z · SHA-256 92834041c829ec5e3939ce6e53a59cbb395dd50a747f887333911f0d0075973f · Passage 6bfbe9349288919cff8744dee8d3ffa08186a2a52087c570527f726ace4c68f4 · Zeichen 1125–1136 im Abschnitt
Wechselwirkungen · Spectrila
Spectrila 10,000 U powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-128260 · Präparat HOS-096541
The toxicity of vincristine may be additive with that of asparaginase if both agents are administered
concomitantly. Therefore, vincristine should be given 3 to 24 hours before administration of
asparaginase in order to minimise toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vincristine (HOS-086219)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T12:00:00Z · SHA-256 92834041c829ec5e3939ce6e53a59cbb395dd50a747f887333911f0d0075973f · Passage 530c2719a0d3db984d6a61c679525eed51a4f236587acf36b5806c6b08e4213d · Zeichen 1138–1376 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-128905 · Präparat HOS-096645
(CYP2B6 induction)
Anti-cancer
Vinca alkaloids (vincristine,
Not studied. No isavuconazole dose
vinblastine) Vinca alkaloid concentrations may adjustment necessary.
(P-gp substrates) increase. Vinca alkaloids: careful
monitoring for any occurrence of
(P-gp inhibition) drug toxicity, and dose reduction
if required.
Cyclophosphamide Not studied. No isavuconazole dose
(CYP2B6, CYP3A4 substrate) Active metabolites of adjustment necessary.
cyclophosphamide concentrations Cyclophosphamide: careful
may increase or decrease. monitoring for any occurrence of
lack of efficacy or increased
(CYP2B6 induction, CYP3A4 toxicity, and dose adjustment if
inhibition) required.
Methotrexate Methotrexate: No isavuconazole dose
(BCRP, OAT1, OAT3 AUCinf: ↓ 3% adjustment necessary.
substrate) Cmax: ↓ 11% Methotrexate: no dose
adjustment required.
7-hydroxymetabolite:
AUCinf: ↑ 29%
Cmax: ↑ 15%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 59c31aafb988b6a4cbbfe1e4ad402b3c90d5d2ef03a62233d8b1bf782f0fbaa2 · Zeichen 10318–11953 im Abschnitt
Wechselwirkungen · Cresemba
CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 31–32
HOS-128987 · Präparat HOS-096645
(CYP2B6 induction)
Anti-cancer
Vinca alkaloids (vincristine,
Not studied. No isavuconazole dose
vinblastine) Vinca alkaloid concentrations may adjustment necessary.
(P-gp substrates) increase. Vinca alkaloids: careful
monitoring for any occurrence of
(P-gp inhibition) drug toxicity, and dose reduction
if required.
Cyclophosphamide Not studied. No isavuconazole dose
(CYP2B6, CYP3A4 substrate) Active metabolites of adjustment necessary.
cyclophosphamide concentrations Cyclophosphamide: careful
may increase or decrease. monitoring for any occurrence of
lack of efficacy or increased
(CYP2B6 induction, CYP3A4 toxicity, and dose adjustment if
inhibition) required.
Methotrexate Methotrexate: No isavuconazole dose
(BCRP, OAT1, OAT3 AUCinf: ↓ 3% adjustment necessary.
substrate) Cmax: ↓ 11%
31
Methotrexate: no dose
7-hydroxymetabolite: adjustment required.
AUCinf: ↑ 29%
Cmax: ↑ 15%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage f297d4e54ac567e12c407f3a10e2d154b27fb2971b0f8c5eb1eafa663ecc87dc · Zeichen 10476–12191 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 11–12
HOS-130932 · Präparat HOS-096981
11
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax ↓ 69% unless the benefit outweighs the
300 mg QD Voriconazole AUCτ ↓ 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax ↓ 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUCτ ↓ 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax ↑ 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUCτ ↑ 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
Voriconazole Cmax ↑ 104% voriconazole.
Voriconazole AUCτ ↑ 87%
Rifampicin (600 mg QD) Voriconazole Cmax ↓ 93% Contraindicated (see section
[potent CYP450 inducer] Voriconazole AUCτ ↓ 96% 4.3)
Anti-cancer agents
Glasdegib Although not studied, voriconazole If concomitant use cannot be
[CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG
concentrations of glasdegib and monitoring is recommended (see
increase risk of QTc prolongation. section 4.4).
Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is
[CYP3A4 substrate] may increase tretinoin recommended during treatment
concentrations and increase risk of with voriconazole and after its
adverse reactions (pseudotumor discontinuation.
cerebri, hypercalcaemia).
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] voriconazole is contraindicated
is likely to significantly increase
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) cabozantinib (HOS-109450) bosutinib (HOS-109449) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage a727a2ab7387474339dda3254656feca43bcab245942f337e8162bae4f84a54b · Zeichen 5317–10081 im Abschnitt
Wechselwirkungen · Oncaspar
Oncaspar 750 U/ml powder for solution for injection/infusion. · Abschnitt 4.5 · PDF-Seite 6
HOS-131521 · Präparat HOS-097087
Immediately preceding or simultaneous treatment with vincristine can increase the toxicity of
pegaspargase. Administration of Oncaspar before vincristine may increase the neurotoxicity of
vincristine. Therefore, vincristine should be given at least 12 hours prior to administration of Oncaspar
in order to minimise toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vincristine (HOS-086219)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T15:25:00Z · SHA-256 76dc9eed7dc8fae840aac8646ddfd5b804f415269fe1e076c1b8ee3a8fd6ae06 · Passage 58a3a57d5bd6d139ada82771866e770408016ad75300f8c574d87cf899c7cb78 · Zeichen 1765–2089 im Abschnitt
Wechselwirkungen · Zydelig
Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132100 · Präparat HOS-097192
Bepridil, disopyramide, ↑ serum concentrations Clinical monitoring is recommended.
lidocaine
ANTI-CANCER AGENTS
Tyrosine kinase inhibitors such ↑ serum concentrations Careful monitoring of the tolerance to
as dasatinib and nilotinib, also these anti-cancer agents is
vincristine and vinblastine recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) lidocaine (HOS-108866) vinblastine (HOS-086220) bepridil (HOS-085612) vincristine (HOS-086219) disopyramide (HOS-085595) tyrosine (HOS-108875) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-21T17:52:00Z · SHA-256 f55f90ba278a87ef1c8e7162344ed4bd66ac7180deaf4c8fda3eca5bbf8e87e5 · Passage dcefc8756545ab9596bcdf86165a73d7cedb48f09cdf62c4f5f6d9d4ce436e7e · Zeichen 3532–3944 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-132861 · Präparat HOS-097310
Monitoring of QT-prolongation if
used concomitantly.
Bortezomib Bortezomib: Careful monitoring.
Busulfan AUC: ↑ 1.4-fold Dose adjustment of each medicinal
Docetaxel Imatinib: product may be required.
Imatinib AUC: ↑ 1.4-fold
Cabazitaxel Cmax: ↑ 1.3-fold
↑in plasma concentrations of
docetaxel have been observed
Potential ↑in plasma concentrations of
busulfan
Cabazitaxel
AUC: ↑ 1.3-fold
Paclitaxel Paclitaxel: Careful monitoring.
No change in plasma concentration were Dose adjustment of paclitaxel
shown with paclitaxel concentrate. No may be required.
studies were performed with albumin
bound nanoparticules.
Vincristine, vinblastine Potential ↑in plasma concentrations of Careful monitoring as it may cause
(vinca alkaloids) vinca alkaloids. an earlier onset and/or an increased
severity of side-effects.
Antipsychotics,
Anxiolytics and
Hypnotics
Triazolam AUC: ↑ have been observed Contraindicated due to the risk of
Alprazolam Cmax: ↑ have been observed potentially prolonged or increased
Midazolam oral sedation and respiratory depression
(see section 4.3).
Lurasidone Lurasidone: Contraindicated due to the increased
AUC: ↑ 9 fold risk of adverse reactions (see section
Cmax: ↑ 6 fold 4.3).
Pimozide Potential ↑in plasma concentrations of Contraindicated due to the risk of
pimozide. serious cardiovascular events
including QT prolongation (see
section 4.3).
Sertindole Potential ↑in plasma concentrations of Contraindicated due to the risk of QT
sertindole. prolongation (see section 4.3).
Quetiapine Quetiapine: Contraindicated as it may increase
AUC: ↑ 6.2-fold quetiapine-related toxicity (see
Cmax: ↑ 3.4-fold section 4.3).
Haloperidol Potential ↑in plasma concentrations of Not recommended due to the
haloperidol. increased risk of QT prolongation
and extrapyramidal symptoms. It
may be necessary to reduce
haloperidol dosage.
Reboxetine Reboxetine: Not recommended because of
AUC: ↑ 1.5-fold of both enantiomers reboxetine narrow’s therapeutic
margin.
Midazolam IV Midazolam: Careful monitoring.
AUC: ↑ 1.6-fold Dose adjustment of midazolam IV
may be required.
11
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Buspirone Potential ↑in plasma concentrations of Careful monitoring.
buspirone. Dose adjustement of buspirone
may be required.
Aripiprazole Aripiprazole Careful monitoring.
AUC: ↑ 1.6-fold Aripiprazole dose should be reduced
Cmax: ↑ 1.4-fold to approximatively one-half of its
prescribed dose.
Risperidone Potential ↑in AUC of risperidone: Careful monitoring. Dose adjustment
of risperidone may be required.
Antivirals products
Saquinavir Saquinavir: Contraindicated due to the risk of QT
(saquinavir/ritonavir AUC: ↔ prolongation (see section 4.3).
1000/100 mg bid) Cmax: ↔
Ketoconazole
AUC: ↑ 2.7-fold
Cmax:↑ 1.5-fold
(CYP3A4 enzyme inhibition by
ritonavir)
Paritaprevir: Contraindicated due to the increased
AUC: ↑2.2-fold risk of adverse reactions (see section
Cmax: ↑1.7-fold 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aripiprazole (HOS-129408) sertindole (HOS-085601) quetiapine (HOS-086150) busulfan (HOS-115553) reboxetine (HOS-132863) alprazolam (HOS-086171) vinblastine (HOS-086220) risperidone (HOS-086280) vincristine (HOS-086219) imatinib (HOS-110212) docetaxel (HOS-084505) saquinavir (HOS-084522) bortezomib (HOS-110227) pimozide (HOS-085600) cabazitaxel (HOS-124028) buspirone (HOS-086325) paclitaxel (HOS-087959) haloperidol (HOS-085602) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 143b60c2365c220e7ae1ab4873f027ce623544d65995b03a1aab29b618d47f97 · Zeichen 15667–21466 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-134501 · Präparat HOS-097580
16
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by
150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of
day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg
darunavir AUC ↑ 53% once every other day) and increased
darunavir Cmin ↑ 68% monitoring for rifabutin related
darunavir Cmax ↑ 39% adverse events is warranted in
**
sum of active moieties of rifabutin patients receiving the combination
(parent drug + 25-O-desacetyl with darunavir co- administered
metabolite) with ritonavir. In case of safety
issues, a further increase of the
The interaction trial showed a dosing interval for rifabutin and/or
comparable daily systemic exposure monitoring of rifabutin levels
for rifabutin between treatment at 300 should be considered.
mg once daily alone and 150 mg once Consideration should be given to
every other day in combination with official guidance on the appropriate
darunavir/ritonavir (600/100 mg twice treatment of tuberculosis in HIV
daily) with an about 10-fold increase in infected patients.
the daily exposure to the active Based upon the safety profile of
metabolite 25-O-desacetylrifabutin. darunavir/ritonavir, the increase in
Furthermore, AUC of the sum of active darunavir exposure in the presence
moieties of rifabutin (parent drug + 25- of rifabutin does not warrant a dose
O- desacetyl metabolite) was increased adjustment for darunavir/ritonavir.
1.6-fold, while Cmax remained Based on pharmacokinetic
comparable. modeling, this dosage reduction of
Data on comparison with a 150 mg 75% is also applicable if patients
once daily reference dose is lacking. receive rifabutin at doses other than
300 mg/day.
(Rifabutin is an inducer and substrate
of CYP3A.) An increase of systemic
exposure to darunavir was observed
when darunavir co-administered with
100 mg ritonavir was co-administered
with rifabutin (150 mg once every
other day).
ANTINEOPLASTICS
Dasatinib Not studied. Darunavir is expected to Concentrations of these medicinal
Nilotinib increase these antineoplastic plasma products may be increased when co-
Vinblastine concentrations. administered with darunavir with
Vincristine (CYP3A inhibition) low dose ritonavir resulting in the
potential for increased adverse
events usually associated with these
agents.
Caution should be exercised when
combining one of these
antineoplastic agents with darunavir
with low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) rifabutin (HOS-086262) vinblastine (HOS-086220) vincristine (HOS-086219) ritonavir (HOS-084521) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 2d29a4cc5ed0b856ce69d677213db7b65a09132fb2ab2fcf31979e5ce17cc212 · Zeichen 37636–41984 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-134625 · Präparat HOS-097580
(Rifabutin is an inducer and
substrate of CYP3A.) An increase
of systemic exposure to darunavir
was observed when darunavir co-
administered with 100 mg ritonavir
was co-administered with rifabutin
(150 mg once every other day).
ANTINEOPLASTICS
Dasatinib Not studied. Boosted darunavir is Concentrations of these medicinal
Nilotinib expected to increase these products may be increased when co-
Vinblastine antineoplastic plasma administered with boosted darunavir
Vincristine concentrations. resulting in the potential for
(CYP3A inhibition) increased adverse events usually
associated with these agents.
Caution should be exercised when
combining one of these antineoplastic
agents with boosted darunavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) rifabutin (HOS-086262) vinblastine (HOS-086220) vincristine (HOS-086219) ritonavir (HOS-084521) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 41e50b54c2b04a09c4b33c1eff5840338665ac8d94894b01c6529d4aab3b77d0 · Zeichen 47228–48580 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-138487 · Präparat HOS-098200
This recommendation is different
from ritonavir-boosted darunavir.
Consult the Summary of Product
Characteristics for darunavir for
further details.
ANTI-NEOPLASTICS
Dasatinib Based on theoretical considerations Concentrations of these medicinal
Nilotinib DRV/COBI is expected to increase products may be increased when
Vinblastine these anti-neoplastic plasma co-administered with Symtuza
Vincristine concentrations. resulting in the potential for
(CYP3A inhibition) increased adverse events usually
associated with these medicinal
products.
Caution should be exercised when
combining one of these
anti-neoplastic agents with
Symtuza.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 00a315d74a37a3357d5f3e656bba8b6b8346a8691f33f70d30e2febf7a8478af · Zeichen 22016–23449 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.